Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5681862 | 0.85 | MEN1 (0.32) | MEN1GMNNGABBR2ALDH1A1LMNA | |
| Propionic Acid SCHEMBL28841722 | 0.82 | FFAR3 (0.48) | MEN1ALDH1A1ALOX15TSHRCYP2C19 | |
| SCHEMBL19621 | 0.76 | — | — | |
| SCHEMBL229715 | 0.76 | ALDH1A1 (0.35) | MEN1GMNNGABBR2ALDH1A1LMNA | |
| SCHEMBL1066136 | 0.76 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL16142531 | 0.74 | — | — | |
| SCHEMBL8204414 | 0.73 | TSHR (0.33) | TSHR | |
| SCHEMBL4980321 | 0.73 | — | — | |
| SCHEMBL13878245 | 0.73 | MEN1 (0.37) | MEN1LMNAKMT2A | |
| SCHEMBL13896428 | 0.73 | MEN1 (0.32) | MEN1GMNNGABBR2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287204-A1 | OXIDIZED POLYISOBUTENE COMPOUNDS AND METHODS OF MAKING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
| EP-4143256-A1 | OXIDIZED POLYISOBUTENE COMPOUNDS AND METHODS OF MAKING THE SAME | The Regents of The University of California (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-110662746-B | Compounds as orally administered prodrugs of beta-lactamase inhibitors, pharmaceutical compositions thereof and use for treating bacterial infections | 阿里萨制药有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021222630-A1 | OXIDIZED POLYISOBUTENE COMPOUNDS AND METHODS OF MAKING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| US-9890198-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9758527-B2 | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2017-09-12 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170114072-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2017-04-27 | — | — | US | disclosed |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1463506-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | Astrazeneca AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055491-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| EP-0937094-A1 | METHOD FOR THE PRODUCTION OF IVERMECTIN | BAYER AG (DE) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998018806-A1 | METHOD FOR THE PRODUCTION OF IVERMECTIN | BAYER AKTIENGESELLSCHAFT (DE) | 1998-05-07 | — | — | WO | disclosed |
| US-4874488-A | USING MERCURY CATALYST AND ULTRAVIOLET RADIATION | YALE UNIVERSITY (US) | 1989-10-17 | — | — | US | disclosed |
| EP-0288557-A1 | PHOTOCHEMICAL DIMERIZATION AND FUNCTIONALIZATION OF ALKANES, ETHERS, PRIMARY AND SECONDARY ALCOHOLS, PHOSPHINE OXIDES AND SILANES | YALE UNIVERSITY (US) | 1988-11-02 | — | — | EP | disclosed |
| WO-1988003436-A1 | PHOTOCHEMICAL DIMERIZATION AND FUNCTIONALIZATION OF ALKANES, ETHERS, PRIMARY AND SECONDARY ALCOHOLS, PHOSPHINE OXIDES AND SILANES | YALE UNIVERSITY (US) | 1988-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | MEN1 3823/4885GMNN 4230/4885GABBR2 4491/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | MEN1 3823/4885GMNN 4230/4885GABBR2 4491/4885 |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | MEN1 1500/4885GMNN 3461/4885GABBR2 824/4885 |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | MEN1 1579/4885GMNN 1030/4885GABBR2 4173/4885 |
| US-20170114072-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | GLP1R, GPR119, GCGR | MEN1 383/4885GMNN 2050/4885GABBR2 3092/4885 |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MEN1 1760/4885GMNN 4766/4885GABBR2 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.